These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 30010900)

  • 1. Prospective cohort study of C-reactive protein as a predictor of clinical events in adults with congenital heart disease: results of the Boston adult congenital heart disease biobank.
    Opotowsky AR; Valente AM; Alshawabkeh L; Cheng S; Bradley A; Rimm EB; Landzberg MJ
    Eur Heart J; 2018 Sep; 39(34):3253-3261. PubMed ID: 30010900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Albuminuria With Major Adverse Outcomes in Adults With Congenital Heart Disease: Results From the Boston Adult Congenital Heart Biobank.
    Rajpal S; Alshawabkeh L; Almaddah N; Joyce CM; Shafer K; Gurvitz M; Waikar SS; Mc Causland FR; Landzberg MJ; Opotowsky AR
    JAMA Cardiol; 2018 Apr; 3(4):308-316. PubMed ID: 29541749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and Prognostic Association of a Clinical Diagnosis of Depression in Adult Congenital Heart Disease: Results of the Boston Adult Congenital Heart Disease Biobank.
    Carazo MR; Kolodziej MS; DeWitt ES; Kasparian NA; Newburger JW; Duarte VE; Singh MN; Opotowsky AR
    J Am Heart Assoc; 2020 May; 9(9):e014820. PubMed ID: 32342722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship of Red Cell Distribution Width to Adverse Outcomes in Adults With Congenital Heart Disease (from the Boston Adult Congenital Heart Biobank).
    Alshawabkeh L; Rajpal S; Landzberg MJ; Emani S; Ephrem G; Gray C; Singh MN; Wu F; Opotowsky AR
    Am J Cardiol; 2018 Nov; 122(9):1557-1564. PubMed ID: 30217370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide, Troponin-T, and Growth-Differentiation Factor 15 in Adult Congenital Heart Disease.
    Baggen VJ; van den Bosch AE; Eindhoven JA; Schut AW; Cuypers JA; Witsenburg M; de Waart M; van Schaik RH; Zijlstra F; Boersma E; Roos-Hesselink JW
    Circulation; 2017 Jan; 135(3):264-279. PubMed ID: 27832613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of soluble ST2 in adults with congenital heart disease.
    Geenen LW; Baggen VJM; van den Bosch AE; Eindhoven JA; Cuypers JAAE; Witsenburg M; Boersma E; Roos-Hesselink JW
    Heart; 2019 Jul; 105(13):999-1006. PubMed ID: 30700520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B-type natriuretic peptide levels predict long-term mortality in a large cohort of adults with congenital heart disease.
    Yumita Y; Xu Z; Diller GP; Kempny A; Rafiq I; Montanaro C; Li W; Gu H; Dimopoulos K; Niwa K; Gatzoulis MA; Brida M
    Eur Heart J; 2024 Jun; 45(23):2066-2075. PubMed ID: 38743452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Significance of Plasma High-Sensitivity C-Reactive Protein in Patients With Hypertrophic Cardiomyopathy.
    Zhu L; Zou Y; Wang Y; Luo X; Sun K; Wang H; Jia L; Liu Y; Zou J; Yuan Z; Hui R; Kang L; Song L; Wang J
    J Am Heart Assoc; 2017 Feb; 6(2):. PubMed ID: 28154166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of galectin-3 in adults with congenital heart disease.
    Baggen VJM; van den Bosch AE; Eindhoven JA; Menting ME; Witsenburg M; Cuypers JAAE; Boersma E; Roos-Hesselink JW
    Heart; 2018 Mar; 104(5):394-400. PubMed ID: 28942393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New York Heart Association (NYHA) classification in adults with congenital heart disease: relation to objective measures of exercise and outcome.
    Bredy C; Ministeri M; Kempny A; Alonso-Gonzalez R; Swan L; Uebing A; Diller GP; Gatzoulis MA; Dimopoulos K
    Eur Heart J Qual Care Clin Outcomes; 2018 Jan; 4(1):51-58. PubMed ID: 28950356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low fasting plasma glucose level predicts morbidity and mortality in symptomatic adults with congenital heart disease.
    Ohuchi H; Yasuda K; Ono S; Hayama Y; Negishi J; Noritake K; Mizuno M; Iwasa T; Miyazaki A; Yamada O
    Int J Cardiol; 2014 Jun; 174(2):306-12. PubMed ID: 24780541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Red cell distribution width in adults with congenital heart disease: A worldwide available and low-cost predictor of cardiovascular events.
    Baggen VJM; van den Bosch AE; van Kimmenade RR; Eindhoven JA; Witsenburg M; Cuypers JAAE; Leebeek FWG; Boersma E; Roos-Hesselink JW
    Int J Cardiol; 2018 Jun; 260():60-65. PubMed ID: 29525069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics and outcomes of heart failure-related hospitalization in adults with congenital heart disease.
    Moussa NB; Karsenty C; Pontnau F; Malekzadeh-Milani S; Boudjemline Y; Legendre A; Bonnet D; Iserin L; Ladouceur M
    Arch Cardiovasc Dis; 2017 May; 110(5):283-291. PubMed ID: 28314706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tuning and external validation of an adult congenital heart disease risk prediction model.
    Geenen LW; Opotowsky AR; Lachtrupp C; Baggen VJM; Brainard S; Landzberg MJ; van Klaveren D; Lingsma HF; Boersma E; Roos-Hesselink JW
    Eur Heart J Qual Care Clin Outcomes; 2022 Jan; 8(1):70-78. PubMed ID: 33313813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substantial Cardiovascular Morbidity in Adults With Lower-Complexity Congenital Heart Disease.
    Saha P; Potiny P; Rigdon J; Morello M; Tcheandjieu C; Romfh A; Fernandes SM; McElhinney DB; Bernstein D; Lui GK; Shaw GM; Ingelsson E; Priest JR
    Circulation; 2019 Apr; 139(16):1889-1899. PubMed ID: 30813762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Old markers, new approach to assessment of risk in heart failure.
    Kodziszewska K; Leszek P; Korewicki J; Piotrowski W
    Kardiol Pol; 2015; 73(6):387-95. PubMed ID: 25563469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of multiple biomarkers for cardiovascular mortality in adult congenital heart disease: comparisons of single-/two-ventricle physiology, and systemic morphologically right/left ventricles.
    Miyamoto K; Takeuchi D; Inai K; Shinohara T; Nakanishi T
    Heart Vessels; 2016 Nov; 31(11):1834-1847. PubMed ID: 26857388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes and healthcare resource utilization in adult congenital heart disease patients with heart failure.
    Tsang W; Silversides CK; Rashid M; Roche SL; Alonso-Gonzalez R; Austin PC; Lee DS
    ESC Heart Fail; 2021 Oct; 8(5):4139-4151. PubMed ID: 34402222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High burden of drug therapy in adult congenital heart disease: polypharmacy as marker of morbidity and mortality.
    Woudstra OI; Kuijpers JM; Meijboom FJ; Post MC; Jongbloed MRM; Duijnhouwer AL; van Dijk APJ; van Melle JP; Konings TC; Zwinderman AH; Mulder BJM; Bouma BJ
    Eur Heart J Cardiovasc Pharmacother; 2019 Oct; 5(4):216-225. PubMed ID: 30903133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exercise intolerance in adult congenital heart disease: comparative severity, correlates, and prognostic implication.
    Diller GP; Dimopoulos K; Okonko D; Li W; Babu-Narayan SV; Broberg CS; Johansson B; Bouzas B; Mullen MJ; Poole-Wilson PA; Francis DP; Gatzoulis MA
    Circulation; 2005 Aug; 112(6):828-35. PubMed ID: 16061735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.